IOVS AJP: Advances in Physiology Education
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2003;44:2702-2707.)
© 2003 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.02-0956
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okabe, K.
Right arrow Articles by Ogura, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okabe, K.
Right arrow Articles by Ogura, Y.

Intraocular Tissue Distribution of Betamethasone after Intrascleral Administration Using a Non-biodegradable Sustained Drug Delivery Device

Komei Okabe, Hideya Kimura, Junko Okabe, Aki Kato, Noriyuki Kunou, and Yuichiro Ogura

From the Department of Ophthalmology, Nagoya City University Medical School, Nagoya, Japan.

PURPOSE. To evaluate the tissue distribution of betamethasone (BM) after implantation of a nonbiodegradable intrascleral implant as a new, controlled intraocular delivery system.

METHODS. Nonbiodegradable intrascleral implants designed to release BM for at least 1 month were placed in the sclera of pigmented rabbits. The BM concentrations in the aqueous humor, vitreous, and retina-choroid were determined by high-performance liquid chromatography (HPLC) at 3, 7, 14, and 28 days after implantation. The BM concentrations in three sections of retina-choroid were also investigated. Retinal toxicity was evaluated by electroretinography and histology.

RESULT. The BM released from the intrascleral implant in vitro and in vivo showed zero-ordered release profiles for 4 weeks. The BM concentrations in the retina-choroid after placement of the intrascleral implants remained higher than effective concentrations for suppressing various inflammatory processes for at least 28 days. The BM concentrations in the retina-choroid around the implantation site were more than 10 times higher than in the opposite side throughout the study. No substantial toxic reactions were observed by electroretinography or histology.

CONCLUSIONS. These findings suggested that the nonbiodegradable intrascleral implant could be a useful drug carrier for intraocular delivery of BM without producing severe retinal toxicity. The intrascleral site may be considered for effective intraocular drug distribution after implantation.




This article has been cited by other articles:


Home page
 IOVSHome page
B. C. Gilger, J. H. Salmon, D. A. Wilkie, L. P. J. Cruysberg, J. Kim, M. Hayat, H. Kim, S. Kim, P. Yuan, S. S. Lee, et al.
A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis.
Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2596 - 2605.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Okabe, H. Kimura, J. Okabe, A. Kato, H. Shimizu, T. Ueda, S. Shimada, and Y. Ogura
Effect of Benzalkonium Chloride on Transscleral Drug Delivery
Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 703 - 708.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. Kato, H. Kimura, K. Okabe, J. Okabe, N. Kunou, and Y. Ogura
Feasibility of Drug Delivery to the Posterior Pole of the Rabbit Eye with an Episcleral Implant
Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 238 - 244.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Association for Research in Vision and Ophthalmology